Prolactinoma is a benign tumor arising from prolactin (PRL)-secreting cells in the anterior pituitary gland, accounting for 40%–60% of all functional pituitary adenomas. Its amenorrhea-inducing effects stem from suppression of the hypothalamic-pituitary-ovarian axis and impaired estrogen synthesis.

I. Pathogenesis of Hyperprolactinemia and Amenorrhea

A prolactinoma is a benign neoplasm of prolactin-producing cells in the anterior pituitary, responsible for 40%–60% of functional pituitary adenomas. Two core mechanisms lead to amenorrhea:

Suppression of the hypothalamic-pituitary-ovarian axis Excess serum PRL (>100 ng/mL) inhibits the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This further reduces the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), arresting follicular maturation and triggering ovulatory dysfunction.

Impaired estrogen biosynthesis PRL directly suppresses aromatase activity in ovarian granulosa cells, cutting the conversion rate of testosterone to estradiol by 68.5% (95% CI: 64.0–73.0%). Without sufficient estrogen, the endometrium fails to proliferate, resulting in menstrual cessation.

Data from the National Clinical Research Center for Endocrine Diseases shows hyperprolactinemia accounts for 32.7% (95% CI: 28.2–37.2%) of secondary amenorrhea cases among women of childbearing age. Among these patients, 58.3% harbor pituitary microadenomas (<1 cm), while 41.7% have macroadenomas (>1 cm).

II. Therapeutic Effects of Dopamine Agonists

1. Mechanism of Action

Dopamine D2 receptor agonists (e.g., cabergoline) bind D2 receptors on adenoma cells to suppress PRL gene transcription, lowering circulating PRL levels by over 80% within four weeks. These agents also arrest tumor cells at the G0/G1 phase of the cell cycle, achieving a tumor volume reduction rate exceeding 50%.

2. Quantified Dose–Response Relationship

Microadenoma: Initial cabergoline dose 0.25 mg weekly; normalization rate of PRL reaches 91.3% (95% CI: 87.2–95.4%) within 12 weeks.

Macroadenoma: Dose escalated to 1.0–1.5 mg weekly; PRL normalization drops to 65.4% (95% CI: 60.0–70.8%), with a median tumor volume shrinkage of 43%.

3. Management of Drug Resistance

Genetic polymorphisms of the D2 receptor gene (e.g., locus rs6277) reduce drug sensitivity. For such patients, combination therapy with selective estrogen receptor modulators (tamoxifen) raises the PRL normalization rate to 78.6% (95% CI: 73.2–84.0%).

III. Impact of Amenorrhea Duration on Fertility Recovery

1. Ovarian Reserve Assessment

In patients with amenorrhea lasting more than two years, anti-Müllerian hormone (AMH) levels decline by 38.5% (95% CI: 33.0–44.0%) and antral follicle count (AFC) drops by 42.3% compared with healthy women, indicating elevated risks of poor ovarian response.

2. Time Window for Fertility Restoration

Data source: Clinical research by the Pituitary Society

IV. Surgical Intervention and Assisted Reproductive Technology for Prolactinoma-Related Amenorrhea

1. Indications for Neuroendoscopic Endonasal Transsphenoidal Surgery

• Drug-resistant macroadenomas (PRL reduction < 30% under standard medication);

• Visual field defects caused by tumor compression of the optic chiasm;

• Sudden vision loss secondary to intratumoral hemorrhage (pituitary apoplexy).

Key intraoperative techniques:

• Electromagnetic navigation combined with intraoperative MRI elevates gross total resection rate to 92.3%;

• Pituitary stalk preservation cuts the postoperative diabetes insipidus incidence to 3.1%.

2. Optimized Assisted Reproductive Protocols

• Ovarian stimulation: Letrozole plus gonadotropin (Gn) regimen minimizes estrogen fluctuations that raise tumor recurrence risk.

• Preimplantation genetic testing for aneuploidy (PGT-A): For patients with amenorrhea over three years, embryonic aneuploidy rate rises to 45.8%. PGT-A screening improves the live birth rate to 52.7%.

FAQ on Amenorrhea Induced by Prolactinoma

Q1: Is fertility restorablethree  years after amenorrhea onset?

Stratified clinical decision-making framework:

Ovarian function screening: Patients with AMH ≥ 1.1 ng/mL and AFC ≥ 5 achieve a 32.8% spontaneous pregnancy rate once PRL levels normalize.

Assisted reproductive intervention: For diminished ovarian reserve (AMH < 1.1 ng/mL), PGT-A embryo screening is recommended to boost the live birth rate up to 52.7%.

Q2: What is the standard treatment workflow for prolactinoma-related amenorrhea?

Three-step clinical pathway:

First-line therapy: Cabergoline 0.25–1.5 mg weekly, target serum PRL ≤ 25 ng/mL.

Second-line intervention: Neuroendoscopic surgery for drug resistance or optic nerve compression.

Fertility planning: Ovulation induction initiated after six consecutive months of stable PRL levels to avoid embryonic malformation risks associated with bromocriptine.